Login
$AMGN
$462.52 +$0.20 (0.04%) After hours

$AMGN 8-K/A SEC Filings

Filed On Filing
27 Jan 2020 8-K/A: Financial Statements and Exhibits

On November 21, 2019, Amgen Inc. (Amgen) completed the acquisition (the “Acquisition”) of certain assets and liabilities associated with the worldwide rights to Otezla® (apremilast) from Celgene Corporation (Celgene) for an aggregate pur...

02 Feb 1995 8-K/A: Financial Statements and Exhibits

Amendment to Current Report Filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support